However, EY's M&A Outlook and Firepower Report strikes an optimistic tone about biopharma M&A in 2018. The report says that thanks to tax reform—particularly incentives to repatriate profits from overseas—M&A activity in the life sciences sector should surge in 2018. According to EY, the top 10 U.S. ...
more here
No comments:
Post a Comment